Promethera collaboration to establish breakthrough cell therapy manufacturing platform

Belgian cell therapy company Promethera Biosciences and Japan’s Shibuya Corp (TYO: 6340) have entered into a strategic collaboration to establish a high-throughput, commercial-scale and clinical-grade cell therapy and regenerative medicine manufacturing platform.

For Promethera, the collaboration will act as a cornerstone to optimize and expand the manufacturing capabilities for its current and future portfolio of liver-derived cell therapies to treat non-alcoholic steatohepatitis (NASH), acute-on-chronic liver-failure (ACLF) and other indications.

For Shibuya, the deal represents a significant step towards bringing the company’s expertise to the European market and becoming a global leader in the manufacturing of regenerative medicine products. Both parties will combine their capabilities and expertise to establish a first-in-class manufacturing facility starting at Promethera’s new premises in Gosselies, Belgium. Financial terms of the agreement were not disclosed.